乳头瘤病毒L1衣壳通过一种蛋白质受体凝集小鼠红细胞。
Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor.
作者信息
Roden R B, Hubbert N L, Kirnbauer R, Breitburd F, Lowy D R, Schiller J T
机构信息
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892, USA.
出版信息
J Virol. 1995 Aug;69(8):5147-51. doi: 10.1128/JVI.69.8.5147-5151.1995.
Abstract
Virus-like particles (VLPs) composed of L1 derived from bovine papillomavirus type 1 (BPV-1), several human papillomavirus types, or cottontail rabbit papillomavirus (CRPV) agglutinated mouse but not human or rat erythrocytes. Treatment of mouse erythrocytes with trypsin prevented hemagglutination (HA) by BPV-1. Sera from rabbits immunized with native CRPV VLPs, which protect against experimental CRPV infection, exhibited high titers of antibodies that inhibited CRPV VLP HA activity, while sera from rabbits immunized with denatured CRPV VLPs or native BPV VLPs, which do not protect against CRPV infection, were not inhibitory. Testing for HA inhibition is a rapid and simple method for examining the serological relatedness of papillomaviruses and measuring protective antibody titers after VLP vaccination.
摘要
由源自1型牛乳头瘤病毒（BPV-1）、多种人乳头瘤病毒类型或棉尾兔乳头瘤病毒（CRPV）的L1组成的病毒样颗粒（VLP）能凝集小鼠红细胞，但不能凝集人或大鼠红细胞。用胰蛋白酶处理小鼠红细胞可防止BPV-1引起的血凝反应（HA）。用天然CRPV VLP免疫的兔子血清可预防实验性CRPV感染，其抗体滴度较高，能抑制CRPV VLP的HA活性，而用变性CRPV VLP或天然BPV VLP免疫的兔子血清（不能预防CRPV感染）则无抑制作用。HA抑制试验是一种快速简便的方法，可用于检测乳头瘤病毒的血清学相关性以及测量VLP疫苗接种后的保护性抗体滴度。
相似文献
1
Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor.乳头瘤病毒L1衣壳通过一种蛋白质受体凝集小鼠红细胞。
J Virol. 1995 Aug;69(8):5147-51. doi: 10.1128/JVI.69.8.5147-5151.1995.
2
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.用棉尾兔乳头瘤病毒（CRPV）的病毒样颗粒进行免疫接种可预防实验性CRPV感染。
J Virol. 1995 Jun;69(6):3959-63. doi: 10.1128/JVI.69.6.3959-3963.1995.
3
Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus.用病毒样颗粒进行免疫可诱导兔子对棉尾兔乳头瘤病毒攻击产生长期保护。
J Virol. 1996 Feb;70(2):960-5. doi: 10.1128/JVI.70.2.960-965.1996.
4
Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation.用酵母表达的棉尾兔乳头瘤病毒（CRPV）病毒样颗粒进行疫苗接种可保护兔子免受CRPV诱导的乳头瘤形成。
Vaccine. 1995 Nov;13(16):1509-14. doi: 10.1016/0264-410x(95)00103-8.
5
Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.通过用人乳头瘤病毒16型次要衣壳抗原L2的N端进行免疫来保护兔子免受兔乳头瘤病毒攻击。
J Virol. 2007 Nov;81(21):11585-92. doi: 10.1128/JVI.01577-07. Epub 2007 Aug 22.
6
Protective cell-mediated immunity by DNA vaccination against Papillomavirus L1 capsid protein in the Cottontail Rabbit Papillomavirus model.在棉尾兔乳头瘤病毒模型中，通过DNA疫苗接种针对乳头瘤病毒L1衣壳蛋白产生保护性细胞介导免疫。
Viral Immunol. 2006 Summer;19(3):492-507. doi: 10.1089/vim.2006.19.492.
7
Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.由L1/L2嵌合病毒样颗粒组成的人乳头瘤病毒疫苗在临床前模型中诱导产生广泛的交叉保护作用。
J Virol. 2016 Jun 24;90(14):6314-25. doi: 10.1128/JVI.00449-16. Print 2016 Jul 15.
8
Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease.用表达棉尾兔乳头瘤病毒L1蛋白的重组水疱性口炎病毒进行鼻内接种可提供针对乳头瘤病毒诱导疾病的完全保护。
J Virol. 2002 Sep;76(17):8900-9. doi: 10.1128/jvi.76.17.8900-8909.2002.
9
Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.牛乳头瘤病毒4型的病毒样颗粒在预防性和治疗性免疫中的应用
Virology. 1996 May 1;219(1):37-44. doi: 10.1006/viro.1996.0220.
10
Antibody-mediated neutralization in vivo of infectious papillomaviruses.体内抗体介导的感染性乳头瘤病毒中和作用。
J Virol. 1990 Jul;64(7):3151-6. doi: 10.1128/JVI.64.7.3151-3156.1990.
引用本文的文献
1
The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease.在治疗 HPV 疾病中使用治疗性和预防性疫苗。
Front Immunol. 2020 Feb 18;11:188. doi: 10.3389/fimmu.2020.00188. eCollection 2020.
2
Development of chimeric candidate vaccine against HPV18: a proof of concept.针对人乳头瘤病毒18型的嵌合候选疫苗的研发：概念验证
Immunol Res. 2015 Jun;62(2):189-97. doi: 10.1007/s12026-015-8650-4.
3
High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses.高通量基于假病毒的中和测定法分析天然和疫苗诱导的人乳头瘤病毒抗体。
PLoS One. 2013 Oct 4;8(10):e75677. doi: 10.1371/journal.pone.0075677. eCollection 2013.
4
A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.一种新型 HPV 16 L1 嵌合病毒样颗粒，包含 E6 和 E7 血清反应性表位，可高度特异性检测 CIN 1 和 HPV-16 感染患者的抗体。
Virol J. 2011 Feb 9;8:59. doi: 10.1186/1743-422X-8-59.
5
Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications.宿主-病原体相互作用中的蛋白聚糖：分子机制及治疗意义。
Expert Rev Mol Med. 2010 Feb 1;12:e5. doi: 10.1017/S1462399409001367.
6
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.研发针对次要衣壳抗原L2的疫苗以预防乳头瘤病毒感染。
Immunol Cell Biol. 2009 May-Jun;87(4):287-99. doi: 10.1038/icb.2009.13.
7
8
Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.人乳头瘤病毒衣壳突变以逃避宫颈癌中树突状细胞依赖性固有免疫。
J Virol. 2005 Jun;79(11):6741-50. doi: 10.1128/JVI.79.11.6741-6750.2005.
9
Induction of immune responses against human papillomaviruses by hypervariable epitope constructs.高变表位构建体诱导针对人乳头瘤病毒的免疫反应
Immunology. 2004 Jun;112(2):321-7. doi: 10.1111/j.1365-2567.2004.01873.x.
10
Cell surface-binding motifs of L2 that facilitate papillomavirus infection.L2的细胞表面结合基序促进乳头瘤病毒感染。
J Virol. 2003 Mar;77(6):3531-41. doi: 10.1128/jvi.77.6.3531-3541.2003.
本文引用的文献
1
Studies on the virus of rabbit papilloma. 1. Methods of assay.兔乳头瘤病毒研究。1. 测定方法。
Aust J Exp Biol Med Sci. 1963 Feb;41:41-50. doi: 10.1038/icb.1963.3.
2
Prospects for cervical cancer vaccines.宫颈癌疫苗的前景。
Cancer Surv. 1993;16:215-29.
3
Synthesis and assembly of infectious bovine papillomavirus particles in vitro.传染性牛乳头瘤病毒颗粒的体外合成与组装
J Gen Virol. 1993 Apr;74 ( Pt 4):763-8. doi: 10.1099/0022-1317-74-4-763.
4
Virus receptors: binding, adhesion strengthening, and changes in viral structure.病毒受体：结合、黏附增强及病毒结构变化
J Virol. 1994 Jan;68(1):1-5. doi: 10.1128/JVI.68.1.1-5.1994.
5
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles.人乳头瘤病毒16型L1和L1-L2高效自组装成病毒样颗粒。
J Virol. 1993 Dec;67(12):6929-36. doi: 10.1128/JVI.67.12.6929-6936.1993.
6
Erythrocyte P antigen: cellular receptor for B19 parvovirus.红细胞P抗原：细小病毒B19的细胞受体。
Science. 1993 Oct 1;262(5130):114-7. doi: 10.1126/science.8211117.
7
Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids.痘苗病毒产生的1型人乳头瘤病毒衣壳的三维结构。
J Virol. 1994 Jul;68(7):4503-5. doi: 10.1128/JVI.68.7.4503-4505.1994.
8
A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.一种病毒样颗粒酶联免疫吸附测定法可检测出大多数感染人乳头瘤病毒16型的女性血清中的抗体。
J Natl Cancer Inst. 1994 Apr 6;86(7):494-9. doi: 10.1093/jnci/86.7.494.
9
Identification and characterization of the cell surface 70-kilodalton sialoglycoprotein(s) as a candidate receptor for encephalomyocarditis virus on human nucleated cells.鉴定并表征细胞表面70千道尔顿唾液酸糖蛋白作为人有核细胞上脑心肌炎病毒的候选受体。
J Virol. 1994 Nov;68(11):7308-19. doi: 10.1128/JVI.68.11.7308-7319.1994.
10
Interaction of papillomaviruses with the cell surface.乳头瘤病毒与细胞表面的相互作用。
J Virol. 1994 Nov;68(11):7260-6. doi: 10.1128/JVI.68.11.7260-7266.1994.
Zotero 插件